KA
CELL

Klingman & Associates’s PhenomeX Inc. Common Stock CELL Stock Holding History

Klingman & Associates’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,005
Closed -$6.37K – 230
2023
Q2 		$6.37K Hold
13,005
– – ﹤0.01% 216
2023
Q1 		$15.1K Buy
+13,005
New +$23.8K ﹤0.01% 199

Other funds holding CELL

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
TAM
Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Klingman & Associates's CELL Position: Q3 2023 in Review

Klingman & Associates sold out of PhenomeX Inc. Common Stock (CELL) in Q3 2023, closing a stake of 13,005 shares — an estimated $6.37K sold.

Klingman & Associates first reported a position in CELL in Q1 2023 and held it in 2 quarters. The position peaked at $15.1K in Q1 2023. 57 funds tracked by Wall St. Rank hold CELL as of Q3 2023.

  • Klingman & Associates reported no remaining PhenomeX Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Klingman & Associates sold 13,005 PhenomeX Inc. Common Stock shares in Q3 2023, an estimated $6.37K.
  • Klingman & Associates first reported a position in PhenomeX Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Klingman & Associates's PhenomeX Inc. Common Stock position peaked at $15.1K in Q1 2023.
  • 57 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q3 2023.

Based on Klingman & Associates's 13F filing for Q3 2023, filed 30 Oct 2023.